Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023

We investigated the efficacy and safety of further bevacizumab therapy in patients with platinum‐resistant ovarian cancer whose disease had progressed after bevacizumab plus chemotherapy. In this multicenter, open‐label, phase II trial (JGOG3023), patients were randomized 1:1 to a single‐agent chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Tadahiro, Enomoto, Takayuki, Abe, Masakazu, Okamoto, Aikou, Nagasawa, Takayuki, Oishi, Tetsuro, Nagase, Satoru, Mori, Masahiko, Inokuchi, Yuki, Kamiura, Shoji, Komiyama, Shinichi, Takeshima, Nobuhiro, Sugiyama, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748228/
https://www.ncbi.nlm.nih.gov/pubmed/34716979
http://dx.doi.org/10.1111/cas.15185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748228/
https://www.ncbi.nlm.nih.gov/pubmed/34716979
http://dx.doi.org/10.1111/cas.15185

Ejemplares similares